Akeso Biopharma, shared on LinkedIn:
“Akeso has entered into a collaboration with Memorial Sloan Kettering Cancer Center (MSKCC) to advance a Phase II clinical study evaluating a cadonilimab-based combination regimen for the perioperative treatment of locally advanced, resectable HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma.
The study is being led by Dr. Yelena Janjigian, Chief, Gastrointestinal Oncology at Memorial Sloan Kettering Cancer Center. It is now actively enrolling patients across the United States.
Building on cadonilimab’s unique dual-target synergistic mechanism, this Phase II study is supported by strong evidence from the Phase III COMPASSION15 trial and previous Phase II neoadjuvant studies in gastric/GEJ adenocarcinoma.
We believe that this Phase II study will generate robust clinical evidence to support the future initiation of an international multicenter Phase III trial of the cadonilimab combination regimen for the perioperative treatment of GC/GEJ adenocarcinoma.”
Other articles about gastric/GEJ adenocarcinoma on OncoDaily.